Manufacturing partnerships support high quality cell therapies Chimeric Therapeutics, Ncardia, and Novartis are some of the companies that have decided to partner to make complex manufacturing processes more efficient for novel therapies, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard.Read More
Focus on drug-manufacturing optimization prioritizes patient health As medical innovations and therapeutics advance rapidly and dramatically increase in scale, there is a critical need for manufacturing processes that can keep up with this pace. This often calls for updates, overhauls, and collaboration among companies to maintain such a high standard of production.Read More
Funding for cell and gene therapies exceeded $70B in 2021 Total funding from all sources for cell and gene therapy companies totaled $70.8 billion last year, according to the recent “Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers, IPOs, and Other Developments” report published by Kalorama Information, a sister company of ScienceBoard.Read More
How one company is helping make complex medicines safer Often, the most dangerous things in life are things that the human eye cannot see. This is true even for life-saving medicines. One company was founded to help the industry find these hidden particles and solve a key challenge in the development of complex drug products. Halo Labs’ CEO Rick Gordon spoke with ScienceBoard about how its low volume approach is providing a critical service for the drug development industry.Read More
Investment into regenerative medicine grows alongside company collaborations Regenerative medicine is a relatively new area of medicine that involves significant research into how to harness the body's own healing mechanisms as treatments for a variety of diseases, including cardiovascular diseases, diabetes, and osteoarthritis. This is performed through the use of stem cell therapies, tissue engineering, and medical devices. The field is rapidly expanding, with many companies forming strategic research partnerships.Read More
mRNA-based therapeutics pioneer innovation in the biopharmaceutical industry In the age of COVID-19, many novel therapeutics have been brought to the forefront, most notably mRNA-based therapies. This technology has been used in two of the most prominent COVID-19 vaccines currently available in the U.S. under the U.S. Food and Drug Administration emergency use authorization. As a result, some companies are expanding mRNA-based technology to apply it to other therapies while further strengthening its use in vaccines.Read More
COVID-19-related sales remain strong for lab tool firms in 2021 Laboratory tool companies have been among the biggest beneficiaries of U.S. government COVID-19-related spending on coronavirus testing and vaccine R&D and manufacturing. COVID-19-related sales have propelled sales at Thermo Fisher Scientific, Danaher, and PerkinElmer, already three of the world's largest scientific instrument and reagent providers.Read More
Sartorius grows operations in France Sartorius is expanding its capacities for production, innovation, and storage in France by investing 100 million euros ($117 million) between 2021 and 2025.Read More
Can cell therapies treat cardiovascular disease? While the development of cell therapies today is largely focused on oncology indications, some companies, including Athersys, envision a future where these therapies could treat other diseases and conditions, such as cardiovascular disease. B.J. Lehmann, interim CEO of Athersys, spoke with ScienceBoard.net about a recent panel that he participated in at the Cell & Gene Meeting on the Mesa 2021.Read More